Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINSHIP-DCM danicamtiv trial in symptomatic genetic and familial dilated cardiomyopathy
2025-522553-19-00Phase 3Authorised
- Sponsor
- Kardigan
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in dilated cardiomyopathy (DCM) comparing Danicamtiv with Placebo (2 arms). Primary endpoints: Change from baseline to Week 26 in left atrial function index and Change from baseline to Week 26 in peak oxygen consumption. Planned start Feb 2026; status: authorised.
02
Drugs
danicamtiv
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2025-522553-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522553-19-00.